Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroaki Ikeda

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|August 3, 2025
[Pharmacotherapy Study of Ophthalmic Solutions and Their Contribution to Patients with Eye Diseases]Hiroaki Ikeda
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|September 11, 2007
[Practice of pharmaceutical care--therapeutic drug monitoring and pharmacoeconomics of glaucoma--]Hiroaki Ikeda
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 22, 2017
[Cancer Immunotherapy Utilizing T Cell Receptor Gene Engineering]Hiroaki Ikeda
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 19, 2018
Gene-modified T cell therapyHiroaki Ikeda
International Immunology|April 30, 2016
T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cellsHiroaki Ikeda
Immunotherapy|March 10, 2012
Gene-modified lymphocytes: from caution to promise for effective cancer immunotherapyHiroaki Ikeda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|July 9, 2019
[Adoptive therapy with TCR gene-modified T cells for hematological malignancies and solid tumors]Hiroaki Ikeda
International Immunology|January 10, 2025
Cancer immunotherapy in progress-an overview of the past 130 yearsHiroaki Ikeda
Cancer Immunology, Immunotherapy : CII|June 5, 2015
Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytesHiroaki Ikeda, Hiroshi Shiku
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 20, 2011
[Cancer vaccine immunotherapy]Hiroaki Ikeda, Hiroshi Shiku
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|August 3, 2025
[Pharmacotherapy Study of Ophthalmic Solutions and Their Contribution to Patients with Eye Diseases]Hiroaki Ikeda
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|September 11, 2007
[Practice of pharmaceutical care--therapeutic drug monitoring and pharmacoeconomics of glaucoma--]Hiroaki Ikeda
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 22, 2017
[Cancer Immunotherapy Utilizing T Cell Receptor Gene Engineering]Hiroaki Ikeda
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 19, 2018
Gene-modified T cell therapyHiroaki Ikeda
International Immunology|April 30, 2016
T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cellsHiroaki Ikeda
Immunotherapy|March 10, 2012
Gene-modified lymphocytes: from caution to promise for effective cancer immunotherapyHiroaki Ikeda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|July 9, 2019
[Adoptive therapy with TCR gene-modified T cells for hematological malignancies and solid tumors]Hiroaki Ikeda
International Immunology|January 10, 2025
Cancer immunotherapy in progress-an overview of the past 130 yearsHiroaki Ikeda
Cancer Immunology, Immunotherapy : CII|June 5, 2015
Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytesHiroaki Ikeda, Hiroshi Shiku
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 20, 2011
[Cancer vaccine immunotherapy]Hiroaki Ikeda, Hiroshi Shiku
Pageof 15